Press Releases

December 14, 2001
Genta Appoints Patrick J. Zenner, Former President and CEO of Hoffmann-La Roche N.A., To Baord of Directors

December 10, 2001
Molecular Target of Genasense^TM Therapy Reaffirmed at ASH Meeting

December 10, 2001
Investigators Report Results of GenasenseTM Studies in Acute Leukemia

December 10, 2001
Investigators Report Results of Genasense^TM  Studies in Chronic Lymphocytic Leukemia

December 3, 2001
Genta Completes Over-Allotment Option in Equity Placement

November 28, 2001
Genta Raises $28.6 Million In Equity Placement

November 14, 2001
Genta and NCI Expand Joint Clinical Trials Program With Genasense^TM  To Include New Types Of Cancer

November 8, 2001
Genasense^TM Clinical Results To Be Discussed at Chemotherapy Foundation Symposium

November 5, 2001
Genta Initiates Multicenter Randomized Trial for Genasense^TM in Patients with Lung Cancer

October 24, 2001
Gentas CEO to present at Techvest, LLC Healthcare Conference

October 12, 2001
New Results from Gentas Gensynergy^TM Program Show Marked Enhancement of Cisplatin Activity by Genasense^TM in Stomach Cancer

October 8, 2001
New Publications Show Gentas Decoy Program Suppresses Key Cancer Genes in Breast and Ovarian Cancer

September 20, 2001
Genta Receives New Fast Track Designation in U.S. and European Orphan Drug Actions for New Cancer Indications

September 4, 2001
Genta Receives Orphan Drug Designation for Three New Cancer Indications

August 17, 2001
Genta Incorporated Announces CEO Conference Call To Be Hosted By Neeham & Company

July 26, 2001
Genta Appoints Alfred J. Fernandez as executive vice-president and Chief Financial Officer

July 25, 2001
Genta Licenses Antisense Technology to EpiGenesis Pharmaceuticals

June 27, 2001
Genta's CEO Highlights Clinical Progress Of Genasense^TM  and Intellectual Property Strength At Major Industry Forum

June 25, 2001
Genasense^TM  Shown To Be Highly Synergistic With Additional Anticancer Drugs At European Hematology Meeting

June 21, 2001
Genta Elects Dr. Betsy McCaughey, Noted Health Care Expert and Former New York State Lieutenant Governor, to its Board of Directors

June 5, 2001
Genta to Present At Wall Street Analyst Forum

May 14, 2001
Investigators Report Clinical Activity Of Genasense^TM  Combination In Prostate Cancer

May 3, 2001
Genta Incorporated Announces First Quarter 2001 Results and Year-To-Date Highlights

April 26, 2001
Genta's Chief Technical Officer Provides Clinical And Manufacturing Update As Keynote Speaker To Industry Conference

April 4, 2001
Genta Appoints Loretta M. Itri, M.D. As Executive Vice President For Clinical Research And Development

April 4, 2001
Genta To Present At Healthcare 2001 Conference Hosted By Tucker Anothony Sutro

April 2, 2001
Genta Announces One Time Non-Recurring Gain For Year-Ended 2000

March 29, 2001
Clinical And Scientific Results Presented Using Genasense^TM  To Enhance Chemotherapy In Colon And Stomach Cancer

March 28, 2001
AACR Presentations Show Bcl-2 Antisense Increases Chemotherapy Activity In Three Lymphoid Cancers

March 27, 2001
New Data Reaffirm Genta's Molecular Target As Critical Factor for Enhancing Anticancer Treatment

March 26, 2001
Lead Investigator Presents Updated Clinical Results For Genasense^TM  Studies In Melanoma At AACR Meeting

March 15, 2001
Genta Presents Clinical Update At International Invesitgator Meetings For Lead Studies of Genasense^TM 

March 5, 2001
Genta Appoints Bruce A. Williams As Senior Vice President, Sales and Marketing

February 28, 2001
Genta Launches New Phase 3 Trial With Genasense^TM  In Chronic Lymphocytic Leukemia

February 13, 2001
Genta Launches Phase 3 Randomized Trial With Genasense^TM  In Multiple Myeloma

February 8, 2001
Genta Announces Fourth Quarter and Year-End 2000 Results and Highlights

February 1, 2001
Genta Announces Election Of Raymond P. Warrell, Jr. As Chairman Of The Board

January 29, 2001
Genta Announces Licensing Of Antisense Technology To Atugen AG

January 19, 2001
Genta Launches New Clinical Trials With Genasense^TM  In Acute And Chronic Leukemia